Skip to main content
. 2021 Nov 17;13(22):5757. doi: 10.3390/cancers13225757

Scheme 4.

Scheme 4

Synthesis of alanine-based analogs lacking the polyisoprenyl moiety (NSL-YHJ-2-31 and NSL-YHJ-2-56).